EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Polypharmacy with tiagabine, levetiracetam, and perampanel in status epilepticus: Insights from EEG, biochemical, and histopathological studies in rats

Sana Javaid, Faleh Alqahtani, Abida Parveen, Waseem Ashraf, Zohabia Rehman, Syed Muhammad Muneeb Anjum, Tanveer Ahmad, Imran Imran iD

Epilepsia Open · 2025

DOI: 10.1002/epi4.13141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Sana Javaid und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Hauptthemen laut MEDLINE: Status Epilepticus, Levetiracetam, Anticonvulsants, Pyridones. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Status epilepticus (SE) is a condition of neurological emergency, which precipitates various functional and morphological changes in the brain. Due to the risk of drug resistance associated with SE, this study aimed to evaluate a multitargeted approach to treat SE by combining clinically used antiseizure drugs.

Methods

In this study, we intraperitoneally administered tiagabine (TGB), levetiracetam (LEV), and perampanel (PER) alone and in combination as a duo and trio therapy after 30 min of SE in electrode‐implanted male Sprague–Dawley rats subjected to lithium–pilocarpine‐induced convulsive SE. The rats were monitored for SE‐associated behavioral and electroencephalographic (EEG) changes. Moreover, at the end of the experiment, rats were sacrificed and brains were excised for biochemical and histopathological evaluation.

Results

The control rats showed behavioral progression to the seizure of Stages 4–5 with 30–40 min of pilocarpine administration along with the appearance of uninterrupted fully blown epileptic spikes on EEG noted up to 2 h. The rats treated with TGB, LEV, and PER alone failed to provide behavioral and ictal attenuation. However, when combinations were tested, there was an improvement in seizure presentation while TGB + PER and LEV + PER also reversed SE‐associated electrographic changes. However, the most prominent seizure attenuation was noted in rats receiving trio therapy with TGB, LEV, and PER. Moreover, the trio‐treated rats demonstrated marked protection from SE‐induced oxidative stress and morphological alterations in different regions of the brains. Significance We observed that intraperitoneal administration of TGB, LEV, and PER alone did not significantly alter the ictal activity recorded by EEG but pharmacological manipulation of acutely coadministered drugs caused a reduction of electrographic, biochemical, and histopathological eruptions providing preclinical evidence of a novel multitargeted combination treatment to ameliorate the acute SE. Plain Language Summary This study investigates and compares the efficacy of mono‐ and polytherapy approach to counter the behavioral, electrographic, and histopathlogical manifestations of status epilepticus. The tiagabine as monotherapy was administered after 30 min of uninterrupted SE, and the outcomes were compared with levetiracetam and perampanel alone as well as their duo and trio combinations. We noted that combining the low doses of tiagabine, levetiracetam, and perampanel notably interrupted the seizure progression through distinct mechanism in rat model of status epilepticus. Thus, we conclude that this novel combination may be a promising multitargeted approach for management of status epilepticus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Status EpilepticusLevetiracetamAnticonvulsantsPyridonesTiagabineAnimalsNitrilesMaleRatsRats, Sprague-DawleyElectroencephalographyDrug Therapy, CombinationDisease Models, AnimalBrainPilocarpine

Stichwörter der Autor:innen

EEGpilocarpinepolytherapystatus epilepticustiagabine

Substanzen

perampanelLevetiracetamAnticonvulsantsNitrilesPyridonesTiagabinePilocarpine

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
  • Department of Pharmacy, The Women University, Multan, Pakistan.
  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • The Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.
  • Institut Pour l'Avancée des Biosciences, Centre de Recherche UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, Grenoble, France.

ORCID-Profile: Imran Imran

Förderung

  • King Saud University

Zitieren

APA

Javaid, S., Alqahtani, F., Parveen, A., Ashraf, W., Rehman, Z., Anjum, S. M. M., Ahmad, T., & Imran, I. (2025). Polypharmacy with tiagabine, levetiracetam, and perampanel in status epilepticus: Insights from EEG, biochemical, and histopathological studies in rats. Epilepsia Open. https://doi.org/10.1002/epi4.13141

Vancouver

Javaid S, Alqahtani F, Parveen A, Ashraf W, Rehman Z, Anjum SMM, et al. Polypharmacy with tiagabine, levetiracetam, and perampanel in status epilepticus: Insights from EEG, biochemical, and histopathological studies in rats. Epilepsia Open. 2025. doi:10.1002/epi4.13141

BibTeX
@article{Javaid2025,
  author = {Javaid, Sana and Alqahtani, Faleh and Parveen, Abida and Ashraf, Waseem and Rehman, Zohabia and Anjum, Syed Muhammad Muneeb and Ahmad, Tanveer and Imran, Imran},
  title = {Polypharmacy with tiagabine, levetiracetam, and perampanel in status epilepticus: Insights from EEG, biochemical, and histopathological studies in rats},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.13141}
}
Kostenlos starten →